ESR1 and breast carcinoma: For tamoxifen-treated and untreated ER-positive patients classified as low risk by the BCI, absolute risks of breast cancer death at 10 years post-diagnosis were 1.1% and 5.1% in their study and 3.5% and 5.1% in ours.